title: Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress.
abstract: To study if cabergoline, a long-lasting specific dopamine D2 receptor agonist, has neuroprotective effects against oxidative stress, we exposed (3 h) SH-SY5Y human neuroblastoma cells to tert-butylhydroperoxide (t-BOOH; 500 microM). t-BOOH caused a 42+/-4% neuronal death, which was prevented by cabergoline (2 h before) in a concentration-dependent manner (EC(50): 1.24 microM). This effect was not antagonised by haloperidol (concentration up to 10 microM), and was associated with an increased availability of intracellular GSH contents (+30+/-11%) and a decrease in the membrane lipid peroxidation (-23+/-9%). Our data suggest that cabergoline has neuroprotective effects useful for Parkinson's disease therapy.
authors.affiliation: DISCAFF Department, University of Piemonte Orientale, Via Bovio 6, 28100 Novara, Italy. lombardi@pharm.unipmn.it
authors.forename: Grazia
authors.initials: G
authors.lastname: Lombardi
authors.forename: Federica
authors.initials: F
authors.lastname: Varsaldi
authors.forename: Gianluca
authors.initials: G
authors.lastname: Miglio
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Papini
authors.forename: Angelo
authors.initials: A
authors.lastname: Battaglia
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Canonico
mesh_terms: D000077465:Cabergoline; D016923:Cell Death / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000494:pharmacology*; D005609:Free Radicals / Q000378:metabolism; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008959:Models, Neurological; D009336:Necrosis; D009474:Neurons / Q000187:drug effects* / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects*; D010300:Parkinson Disease / Q000378:metabolism / Q000517:prevention & control; D017448:Receptors, Dopamine D2 / Q000819:agonists; D014407:Tumor Cells, Cultured; D020122:tert-Butylhydroperoxide / Q000633:toxicity
chemical_list: D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D004873:Ergolines; D005609:Free Radicals; D018696:Neuroprotective Agents; D017448:Receptors, Dopamine D2; D020122:tert-Butylhydroperoxide; D006220:Haloperidol; D000077465:Cabergoline